Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.
Dousset L, Poizeau F, Robert C, Mansard S, Mortier L, Caumont C, Routier É, Dupuy A, Rouanet J, Battistella M, Greliak A, Cappellen D, Galibert MD, Allayous C, Lespagnol A, Gerard É, Kerneuzet I, Roy S, Dutriaux C, Merlio JP, Vergier B, Schrock AB, Lee J, Ali SM, Kammerer-Jacquet SF, Lebbé C, Beylot-Barry M, Boussemart L. Dousset L, et al. Among authors: boussemart l. JCO Precis Oncol. 2021 Dec 16;5:PO.21.00084. doi: 10.1200/PO.21.00084. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34950838 Free PMC article.
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C. Arnault JP, et al. Among authors: boussemart l. Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096025
Vemurafenib and radiosensitization.
Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C. Boussemart L, et al. JAMA Dermatol. 2013 Jul;149(7):855-7. doi: 10.1001/jamadermatol.2013.4200. JAMA Dermatol. 2013. PMID: 23699661
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S. Boussemart L, et al. Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27. Nature. 2014. PMID: 25079330
Metastatic melanoma: New paradigms of treatment and new toxicities.
Robert C, Mateus C, Routier E, Thomas M, Boussemart L, Eggermont AM. Robert C, et al. Among authors: boussemart l. EJC Suppl. 2013 Sep;11(2):278-80. doi: 10.1016/j.ejcsup.2013.07.046. EJC Suppl. 2013. PMID: 26217144 Free PMC article. Review. No abstract available.
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.
Boussemart L, Girault I, Malka-Mahieu H, Mateus C, Routier E, Rubington M, Kamsu-Kom N, Thomas M, Tomasic G, Agoussi S, Breckler M, Laporte M, Lacroix L, Eggermont AM, Cavalcanti A, Grange F, Adam J, Vagner S, Robert C. Boussemart L, et al. Cancer Res. 2016 Mar 15;76(6):1476-84. doi: 10.1158/0008-5472.CAN-15-2900-T. Epub 2016 Jan 29. Cancer Res. 2016. PMID: 26825172
Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
Sfecci A, Dupuy A, Dinulescu M, Droitcourt C, Adamski H, Hadj-Rabia S, Odent S, Galibert MD, Boussemart L. Sfecci A, et al. Among authors: boussemart l. J Invest Dermatol. 2017 Apr;137(4):805-809. doi: 10.1016/j.jid.2016.12.012. J Invest Dermatol. 2017. PMID: 28340684 Free article. Review.
35 results